Skip directly to content

TAGline 2014

NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS

TAGline Fall 2014: hello generics

  • A Drug by Any Other Name
    The basics of generic medications, bioequivalence, and the push for good manufacturing practices
     
  • The Road to Treatment Access
    Generic drug registration, licensing, and a trip to Gilead’s islands
     
  • Safeguarding against Stock-Outs
    The time has come for U.S. tuberculosis programs to have full access to the Stop TB Partnership’s Global Drug Facility procurement and stockpile safety nets
     
  • Generics vs. the Giant
    For people with drug-resistant tuberculosis (DR-TB), generic linezolid may be a lifesaver. But only if quality-assured versions are available and affordable
     


TAGline Spring 2014: The April Fool's Issue

  • Fool Us Once…
    By Tim Horn
    We’re being duped by our government agencies. We’re being hoodwinked by the Affordable Care Act (ACA). We’re being bamboozled by pharmaceutical companies and research networks. In this April Fools’ issue of TAGline, we highlight several missteps in research and policy that have required some degree of advocacy to remedy and ensure that the jokes don’t remain on us.
     
  • Forgotten Negatives: The Limits of Treatment as Prevention
    The CDC’s High-Impact Prevention strategy takes aim at the stubborn HIV incidence rate in the United States. The only problem: it doesn’t include an ambitious plan for those at risk for the virus
     
  • The White House’s Fuzzy Math
    An Office of National AIDS Policy progress report obscures the state of the domestic U.S. HIV/AIDS response
     
  • Marketplace Menaces: Discriminatory Practices by the ACA’s Qualified Health Plans
    Advocates scramble to stay ahead of coverage rejections, formulary concerns, and exorbitant out-of-pocket expenses facing people living with HIV
     
  • Better Late Than Never: Efavirenz Dose Optimization
    After a study suggests that we’ve been using too high a dose of efavirenz for a decade and a half, the move toward scaling up a lower and more cost-effective one faces some hurdles
     
  • Punked by Pharma: Public Funds for Private Products
    Tax dollars are making it easier for the drug and diagnostics industry to develop and market essential TB products. Is the public getting a fair return on its investment?
     
  • Fool’s Errand: The Sloppy Science of the MDR-TB STREAM Trial
    Confirming the efficacy and safety of bedaquiline-inclusive regimens is a priority.